Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

Details

Instance of

clinical trial

Start time

August 2007

End time

October 2011

Country

Belarus, Bulgaria, Egypt, India, Israel, Italy, Poland, Romania, Ukraine, United Kingdom, United States

Main subject

thyroid cancer, multiple endocrine neoplasia type 2A

clinical trial phase

phase II clinical trial, phase III clinical trial

minimum age

18

number of participants

80

research intervention

paclitaxel, fosbretabulin, (R)-(-)-combretastatin, carboplatin

research site

Emory University, Oregon Health and Science University, West Virginia University, All India Institute of Medical Sciences, Patna, Ruby Hall Clinic, MaxCure Hospitals

research subject recruitment status

terminated

short name

FACT

sponsor

Mateon Therapeutics (United States)

study type

interventional study

title

A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT]